You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
|
|---|---|
| Published in |
Frontiers in Medicine, February 2018
|
| DOI | 10.3389/fmed.2017.00220 |
| Pubmed ID | |
| Authors |
Phillip J. Groden, Thomas C. Lee, Shamik Bhattacharyya, Jean Connors, Jochen Lorch |
| Abstract |
Lenvatinib is a tyrosine kinase inhibitor (TKI) approved by the FDA for the treatment of radioiodine-refractory (RAIR) thyroid cancers. Side effects can be severe, however, and include headaches, hypertension, arterial and venous thromboembolic events, and fatalities. Cervical artery dissections (CADs) are leading contributors of cerebral ischemia in young adults, yet the pathophysiology is poorly understood. Here, we describe a case of a 34-year-old female with recurrent, metastatic, RAIR papillary thyroid cancer who, following her second week of lenvatinib treatment, developed significant CAD which resolved following the termination of the TKI therapy. Given the lack of risk factors for the disorder in the patient's history, the known cardiovascular events associated with the drug, previously described cases of arterial dissections linked to VEGF inhibitors, and the temporal relationship between the onset of symptoms and the treatment start date, a causal relationship between the CAD and lenvatinib is suggested. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 18% |
| Other | 2 | 18% |
| Unspecified | 1 | 9% |
| Student > Bachelor | 1 | 9% |
| Unknown | 5 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 1 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
| Biochemistry, Genetics and Molecular Biology | 1 | 9% |
| Computer Science | 1 | 9% |
| Earth and Planetary Sciences | 1 | 9% |
| Other | 1 | 9% |
| Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2018.
All research outputs
#18,589,103
of 23,025,074 outputs
Outputs from Frontiers in Medicine
#4,010
of 5,796 outputs
Outputs of similar age
#256,750
of 330,325 outputs
Outputs of similar age from Frontiers in Medicine
#82
of 107 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,796 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,325 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.